3:15PM 11/12/2014 – Discussion Complex Disorders @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« 1:45PM 11/12/2014 – Panel Discussion – Oncology @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

4:00PM 11/12/2014 – Panel Discussion Novel Approaches to Personalized Medicine @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston »

3:15PM 11/12/2014 – Discussion Complex Disorders @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

November 12, 2014 by 2012pharmaceutical

3:15PM 11/12/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com

3:15 p.m. Discussion Complex Disorders

Complex Disorders

During the past 30-40 years, it has become well established that most human disorders affecting large groups of individuals have a genetic basis. Based upon this information there are several efforts to conduct genetic analysis on very large populations of individuals to identify genetic factors that cause susceptibility to complex disorders. In this session, two examples where such studies are bearing fruit will be discussed.

Complex Disorders

Discussion Leader:

Anna Barker, Ph.D.
Director, Transformative Healthcare Knowledge Networks;
Co-Director, Complex Adaptive Systems Initiative:
Professor, School of Life Sciences, Arizona State University

World of Biomarkers following NIH Career – Molecular based Medicine

get all the facts right straight then distort them

Speakers:

Roy Perlis, MGH, Bipolar Specialty, Prof of Psychiatry

Specialist in Schizophrenia, Autism

Complexity – overlapping diseases, genomics discovery
Psychiatry Genomics – Susceptibility, variance explained by common variation, intervention studies for susceptibility
depression is hereditary
2000 schizophrenics genome,
phenotype models is only partially indicative of help if you are on Klonopin, is this enough for the diagnosis
CRISPR — HOW to use it — not discovered yet for psychiatry disorder — it may be the solution, though

Joe Vockley

COO, Inova Health System

CSO, Inova Translational Medicine Institute

Preeclempsia – preterm Birth is a complex disease many factor can cause it, 12% of birth are Preterm birth
10,000 genome vs full term birth, clinical phenotypes,
model 81% predictive — triage screening based on markers – genomics to follow phenotyping.
Genomics — indicative — not fully used from diagnostics to therapy
ancestor data (familial info) of the 10,000 in the cohort was done filter variant
whole genome sequencing, reimbursement does not support to path to therapy based on genomics

Robert Plenge, M.D., Ph.D. @rplenge
Vice President and Worldwide Head Genetics and Pharmacogenomics
Merck Research Laboratories – Specialist RA

ex- Pharmacogenetics at MGH

sample size 100,000 genomes completely sequenced – PM is at present in Oncology – use Genetics to discover diagnostics markers, clinical diagnosis, protocols – worst in cancer
genetic effect are important component requires big cohort to identify large effect
dysfunctional variant
Proteomic predictors, in drug discovery not sufficient, marker of disease it is helpful

– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf